Designer molecule may lead to new treatments for ocular cancers.
Schultz
James
J
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D015195:Drug Design; D005134:Eye Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D015696:Gene Products, tat / Q000187:drug effects* / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D009363:Neoplasm Proteins / Q000187:drug effects; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins / Q000187:drug effects* / Q000378:metabolism / Q000494:pharmacology*; D051736:Proto-Oncogene Proteins c-mdm2; D011817:Rabbits; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
D000970:Antineoplastic Agents; D015696:Gene Products, tat; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; C470303:Tat-anti-HDM2; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2